At Work With: Rick Conrad

Rick Conrad
Rick Conrad
RICK CONRAD
Associate Creative Director/Art, AbelsonTaylor

What was your biggest break?
My biggest break was my first design job as an Art Director for a publishing company. The job opened the door to many creative opportunities, including writing and illustrating comics and designing music posters and record covers.

Who is the person you admire most in your area of work?
To me, agencies that do breakthrough work, like Wieden Kennedy, CP+B, and studios like Superfad and Psyop are inspirational. I also admire people who “dabble” in different areas of the arts, expressing themselves in art, music and film, like David Lynch, Julian Schnabel and Nick Cave.

What was your greatest professional challenge?
My biggest challenge was also one of the most satisfying: running my own ad agency. At 28, I started Spy Advertising, a creative-driven boutique. As VP/Executive Creative Director, I was involved in every aspect of running an agency.

Where will you be in five years?
I'd like to think I found a home at AbelsonTaylor. I want to take advantage of the wonderful creative opportunities that AT has to offer.

You must be a registered member of MMM to post a comment.
close

Next Article in Careers

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.